AVROBIO, Inc. Stock Price, News & Analysis

AVROBIO, Inc. (Nasdaq: AVRO) has announced promising new data from its clinical programs in Gaucher disease type 1, Fabry disease, and cystinosis, highlighting the efficacy of ex vivo lentiviral gene therapy for lysosomal disorders. Notable results include a 22% reduction in the toxic metabolite plasma lyso-Gb1 for Gaucher disease patients, planning for accelerated approvals in Fabry disease, and positive outcomes for cystinosis patients. Furthermore, AVROBIO is expanding its pipeline with new programs targeting Gaucher disease type 3 and Hunter syndrome, showcasing its commitment to innovative therapies.

AVROBIO, Inc. (Nasdaq: AVRO) has granted non-statutory stock options for 52,250 shares of common stock to four new employees as inducement awards under its 2019 Inducement Plan. These options, approved by the Board’s Compensation Committee on Nov. 2, 2020, have an exercise price of $13.84 per share, aligning with the closing stock price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary and the remaining shares vesting monthly. This move aims to enhance recruitment and retention of talent in line with the company’s growth objectives.

AVROBIO, Inc. (Nasdaq: AVRO) is hosting a Virtual R&D Day on Nov. 17, 2020, at 9:00 a.m. ET to update analysts and investors on its clinical programs. The agenda includes initial data on the Phase 1/2 trial for Gaucher disease, new findings from the cystinosis trial, and updates from Fabry disease trials. The session will discuss advancements in AVROBIO's plato® gene therapy platform and future lentiviral gene therapy programs, including one for Hunter syndrome. Key opinion leaders will also provide insights.

AVROBIO, Inc. (Nasdaq: AVRO) has appointed Gail M. Farfel, Ph.D., to its Board of Directors. With over 25 years of experience in pharmaceutical development and regulatory affairs, particularly in rare diseases, Dr. Farfel aims to drive growth in AVROBIO's investigational gene therapies targeting lysosomal disorders. Her previous roles included executive positions at Zogenix and Novartis, where she led global product development and regulatory strategies. This strategic appointment is expected to enhance AVROBIO's pipeline and strengthen its expertise in gene therapy for rare diseases.

AVROBIO, Inc. (Nasdaq: AVRO), a clinical-stage gene therapy company, has granted non-statutory stock options for 351,250 shares to six new employees as inducement awards. These options, part of the 2019 Inducement Plan, were approved by the Board's Compensation Committee. Granted on Oct. 1, 2020, the exercise price is $13.46 per share, matching the closing price on that date. The options have a 10-year term and vest over four years, with 25% vesting after the first anniversary and the rest in monthly installments, contingent on employee service.

AVROBIO, Inc. (Nasdaq: AVRO) has entered an exclusive license and collaborative research agreement with The University of Manchester for a lentiviral gene therapy aimed at treating Hunter syndrome, a severe lysosomal disorder affecting boys. Hunter syndrome poses serious health challenges, including cognitive decline. The investigational therapy, AVR-RD-05, aims to address these issues by using patients' own stem cells to produce essential enzymes. The Phase 1/2 trial is set to commence in late 2021, with financing terms including upfront payments and royalties based on product sales.

AVROBIO, Inc. (Nasdaq: AVRO) announced that the European Commission has granted orphan drug designation for AVR-RD-02, its investigational gene therapy for Gaucher disease, which affects an estimated 1 in 44,000 people. AVR-RD-02 uses genetically modified hematopoietic stem cells to produce the enzyme glucocerebrosidase (GCase), addressing the disease's debilitating symptoms with a single dose. The therapy also received orphan drug designation from the U.S. FDA. This status offers regulatory benefits and ten years of market exclusivity upon approval.